HKSE - Delayed Quote • HKD
Brii Biosciences Limited (2137.HK)
At close: April 26 at 4:08 PM GMT+8
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | 57.2M |
| Low Estimate | -- | -- | -- | 32.73M |
| High Estimate | -- | -- | 55.6M | 464.25M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.35 | 0.07 | -4.18 | -0.92 |
| 30 Days Ago | -0.35 | 0.07 | -4.18 | -0.92 |
| 60 Days Ago | -0.35 | 0.07 | -4.18 | -0.92 |
| 90 Days Ago | -0.35 | 0.07 | -4.18 | -0.92 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | 2137.HK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 5.40% |
| Next Qtr. | -- | -- | -- | 10.90% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
1873.HK Viva Biotech Holdings
0.560
0.00%
2197.HK Clover Biopharmaceuticals, Ltd.
0.360
+9.09%
1877.HK Shanghai Junshi Biosciences Co., Ltd.
10.740
+4.88%
9939.HK Kintor Pharmaceutical Limited
0.960
+2.13%
6160.HK BeiGene, Ltd.
91.950
+2.17%
2179.HK Jiangsu Recbio Technology Co., Ltd.
9.130
0.00%
AVXT AVAX Technologies, Inc.
0.0001
0.00%
002252.SZ Shanghai RAAS Blood Products Co., Ltd.
7.19
-0.96%
1477.HK Ocumension Therapeutics
6.470
+7.83%
41X.F Ardelyx, Inc.
5.83
-3.60%